Works matching DE "PEMBROLIZUMAB"
Results: 1243
Case with metastatic cutaneous malignant melanoma that developed Vogt–Koyanagi–Harada-like uveitis following pembrolizumab treatment.
- Published in:
- Documenta Ophthalmologica, 2021, v. 142, n. 3, p. 353, doi. 10.1007/s10633-020-09800-0
- By:
- Publication type:
- Article
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
- Published in:
- Cancer & Metastasis Reviews, 2021, v. 40, n. 2, p. 537, doi. 10.1007/s10555-021-09972-4
- By:
- Publication type:
- Article
Impressive response on pembrolizumab monotherapy in a patient with metastatic NSCLC and multiple comorbidities: case report.
- Published in:
- Oncolog-Hematolog, 2023, n. 64, p. 48
- By:
- Publication type:
- Article
Advanced nasopharygeal carcinoma with emphases to medical treatment.
- Published in:
- Oncolog-Hematolog, 2015, n. 31, p. 26
- By:
- Publication type:
- Article
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.
- Published in:
- Vaccines, 2022, v. 10, n. 4, p. N.PAG, doi. 10.3390/vaccines10040540
- By:
- Publication type:
- Article
Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer.
- Published in:
- Vaccines, 2020, v. 8, n. 4, p. 730, doi. 10.3390/vaccines8040730
- By:
- Publication type:
- Article
Combining lenvatinib and pembrolizumab for the management of endometrial carcinosarcoma: a retrospective case series.
- Published in:
- European Journal of Gynaecological Oncology, 2024, v. 45, n. 5, p. 174, doi. 10.22514/ejgo.2024.106
- By:
- Publication type:
- Article
Pembrolizumab monotherapy in heavily treated recurrent cervical cancer patients: case series report.
- Published in:
- European Journal of Gynaecological Oncology, 2023, v. 44, n. 3, p. 57, doi. 10.22514/ejgo.2023.038
- By:
- Publication type:
- Article
Real-world data on efficacy and safety of pembrolizumab in the first-line treatment of metastatic lung cancer in patients with PD-L1 expression >0% - a single center experience.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2023, v. 27, n. 19, p. 9213
- By:
- Publication type:
- Article
Comparative efficacy and safety of PD-1/PD-L1 immunotherapies for non-small cell lung cancer: a network meta-analysis.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2021, v. 25, n. 7, p. 2866
- By:
- Publication type:
- Article
[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.
- Published in:
- Neuro-Oncology Practice, 2022, v. 9, n. 3, p. 246, doi. 10.1093/nop/npac021
- By:
- Publication type:
- Article
Pembrolizumab induced refractory ocular myasthenia gravis: A case report.
- Published in:
- New Zealand Medical Student Journal, 2021, n. 33, p. 30, doi. 10.57129/zehr3311
- By:
- Publication type:
- Article
Eosinophilia as a predictor of response to immune checkpoint inhibition in patients with metastatic melanoma.
- Published in:
- New Zealand Medical Student Journal, 2021, n. 32, p. 22, doi. 10.57129/aeyk1627
- By:
- Publication type:
- Article
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer.
- Published in:
- Clinical & Translational Medicine, 2020, v. 10, n. 1, p. 107, doi. 10.1002/ctm2.14
- By:
- Publication type:
- Article
Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1291090
- By:
- Publication type:
- Article
Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1348045
- By:
- Publication type:
- Article
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1283266
- By:
- Publication type:
- Article
Case Report: Prolonged remission of metastatic cisplatin- refractory nasopharyngeal carcinoma with Pembrolizumab.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1249453
- By:
- Publication type:
- Article
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma--a phase II trial of the AIO study group (AIO STO 0321).
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1272175
- By:
- Publication type:
- Article
Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1232476
- Publication type:
- Article
Corrigendum: Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1240947
- Publication type:
- Article
Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1160144
- By:
- Publication type:
- Article
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16- positive squamous cell carcinoma of unknown primary.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1231986
- By:
- Publication type:
- Article
Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1145986
- By:
- Publication type:
- Article
Cost-effectiveness and budget impact of pembrolizumab +axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1205700
- By:
- Publication type:
- Article
Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1160144
- By:
- Publication type:
- Article
Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1147903
- By:
- Publication type:
- Article
Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1110638
- By:
- Publication type:
- Article
Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1080998
- By:
- Publication type:
- Article
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1128176
- By:
- Publication type:
- Article
Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.1079716
- By:
- Publication type:
- Article
Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2022.960116
- By:
- Publication type:
- Article
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
- Published in:
- Frontiers in Immunology, 2023, v. 13, p. 1, doi. 10.3389/fimmu.2022.1079342
- By:
- Publication type:
- Article
Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.978266
- By:
- Publication type:
- Article
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.882471
- By:
- Publication type:
- Article
Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 01, doi. 10.3389/fimmu.2022.941092
- By:
- Publication type:
- Article
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.896752
- By:
- Publication type:
- Article
Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.823842
- By:
- Publication type:
- Article
Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.864202
- By:
- Publication type:
- Article
Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.893179
- By:
- Publication type:
- Article
Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.799636
- By:
- Publication type:
- Article
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2020, v. 11, p. 53, doi. 10.2147/LCTT.S254146
- By:
- Publication type:
- Article
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 1, doi. 10.2147/LCTT.S105678
- By:
- Publication type:
- Article
Targeting PD-I/PD-LI in lung cancer: current perspectives.
- Published in:
- Lung Cancer: Targets & Therapy, 2015, v. 6, p. 55, doi. 10.2147/LCTT.S55176
- By:
- Publication type:
- Article
Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer.
- Published in:
- Case Reports in Endocrinology, 2021, p. 1, doi. 10.1155/2021/5521649
- By:
- Publication type:
- Article
Myxedema Coma: A Life-Threatening Condition in Patients Using Pembrolizumab.
- Published in:
- Case Reports in Endocrinology, 2020, p. 1, doi. 10.1155/2020/8855943
- By:
- Publication type:
- Article
Dramatic Response to First Line Single Agent Pembrolizumab in Anaplastic Thyroid Carcinoma.
- Published in:
- Case Reports in Endocrinology, 2019, p. 1, doi. 10.1155/2019/9095753
- By:
- Publication type:
- Article
A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient.
- Published in:
- Case Reports in Endocrinology, 2019, p. 1, doi. 10.1155/2019/2314032
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy in systemic lupus erythematosus managed with pembrolizumab: A case report with literature review.
- Published in:
- Lupus, 2021, v. 30, n. 11, p. 1849, doi. 10.1177/09612033211035443
- By:
- Publication type:
- Article